• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    3/6/23 12:31:23 PM ET
    $ACRS
    $ADAP
    $AMAM
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACRS alert in real time by email

    Gainers

    • Unicycive Therapeutics (NASDAQ:UNCY) stock moved upwards by 151.2% to $1.23 during Monday's regular session. Trading volume for this security as of 12:30 EST is 77.1 million, which is 22303.6% of its average full-day volume over the last 100 days. The company's market cap stands at $18.5 million.
    • Bellerophon Therapeutics (NASDAQ:BLPH) stock increased by 82.49% to $3.3. Bellerophon Therapeutics's stock is trading at a volume of 11.1 million shares as of 12:30 EST. This is 1023.2% of its average full-day volume over the last 100 days. The company's market cap stands at $31.4 million.
    • BridgeBio Pharma (NASDAQ:BBIO) stock rose 58.0% to $17.18. Trading volume for BridgeBio Pharma's stock is 22.6 million as of 12:30 EST. This is 1535.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.5 billion.
    • Ambrx Biopharma (NYSE:AMAM) shares rose 42.3% to $9.15. Trading volume for this security as of 12:30 EST is 16.5 million, which is 247.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $353.3 million.
    • TCR2 Therapeutics (NASDAQ:TCRR) stock increased by 38.01% to $1.67. TCR2 Therapeutics's stock is trading at a volume of 15.1 million shares as of 12:30 EST. This is 5588.8% of its average full-day volume over the last 100 days. The company's market cap stands at $64.5 million.
    • Kala Pharmaceuticals (NASDAQ:KALA) stock moved upwards by 33.37% to $22.34. As of 12:30 EST, Kala Pharmaceuticals's stock is trading at a volume of 7.2 million, which is 292.0% of its average full-day volume over the last 100 days. The company's market cap stands at $41.7 million. As per the news, the Q4 earnings report came out yesterday.

    Losers

    • Aclaris Therapeutics (NASDAQ:ACRS) shares fell 47.1% to $6.76 during Monday's regular session. Trading volume for Aclaris Therapeutics's stock is 10.9 million as of 12:30 EST. This is 1842.7% of its average full-day volume over the last 100 days. The company's market cap stands at $450.9 million.
    • Rubius Therapeutics (NASDAQ:RUBY) shares declined by 26.83% to $0.09. As of 12:30 EST, Rubius Therapeutics's stock is trading at a volume of 10.1 million, which is 265.9% of its average full-day volume over the last 100 days. The company's market cap stands at $8.2 million.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) stock fell 23.87% to $1.34. Trading volume for Adaptimmune Therapeutics's stock is 3.2 million as of 12:30 EST. This is 1020.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $219.5 million. The company's, Q4 earnings came out today.
    • Esperion Therapeutics (NASDAQ:ESPR) shares fell 20.43% to $5.04. As of 12:30 EST, Esperion Therapeutics's stock is trading at a volume of 11.5 million, which is 512.6% of its average full-day volume over the last 100 days. The company's market cap stands at $386.3 million.
    • Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock declined by 20.35% to $5.48. Trading volume for this security as of 12:30 EST is 1.4 million, which is 39.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $52.1 million.
    • Organogenesis Hldgs (NASDAQ:ORGO) stock fell 16.1% to $2.45. As of 12:30 EST, this security is trading at a volume of 1.8 million shares, making up 256.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $321.3 million. As per the press release, Q4 earnings came out 3 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRS
    $ADAP
    $AMAM
    $BBIO

    CompanyDatePrice TargetRatingAnalyst
    BridgeBio Pharma Inc.
    $BBIO
    3/10/2026Outperform
    William Blair
    BridgeBio Pharma Inc.
    $BBIO
    1/28/2026$157.00Overweight
    Barclays
    BridgeBio Pharma Inc.
    $BBIO
    1/6/2026$96.00Overweight
    Morgan Stanley
    BridgeBio Pharma Inc.
    $BBIO
    12/11/2025$94.00Outperform
    Bernstein
    Esperion Therapeutics Inc.
    $ESPR
    11/25/2025$9.00Overweight
    Piper Sandler
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    H.C. Wainwright
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    Ladenburg Thalmann
    More analyst ratings

    $ACRS
    $ADAP
    $AMAM
    $BBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on BridgeBio Pharma

    William Blair initiated coverage of BridgeBio Pharma with a rating of Outperform

    3/10/26 8:40:05 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on BridgeBio Pharma with a new price target

    Barclays initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $157.00

    1/28/26 7:16:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on BridgeBio Pharma with a new price target

    Morgan Stanley initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $96.00

    1/6/26 8:54:42 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $AMAM
    $BBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

    PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that long-term efficacy and safety data in patients with ATTR-CM from the open-label extension (OLE) trial of ATTRibute-CM, its Phase 3 study of acoramidis, will be shared in a late-breaking oral presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in New Orleans, Louisiana on March 28-30, 2026. Additionally, BridgeBio was selected to share three posters on additional OLE data and real-world survey findings. Late-Break

    3/23/26 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on March 18, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 29 new employees in restricted stock units for an aggregate of 70,916 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on February 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case

    3/20/26 4:01:00 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

    WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that an ePoster on the results from its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), will be available during the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO. The poster will include results not previously reported from Aclaris' Phase 2a trial in patients with moderate-to-severe atopic dermatitis (AD). Elect

    3/20/26 11:00:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $AMAM
    $BBIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $AMAM
    $BBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Trimarchi Thomas

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    3/20/26 4:33:58 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Apuli Maricel

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    3/20/26 4:32:18 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kumar Neil

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    3/19/26 4:28:10 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $AMAM
    $BBIO
    SEC Filings

    View All

    SEC Form D filed by KALA BIO Inc.

    D - KALA BIO, Inc. (0001479419) (Filer)

    3/17/26 4:59:15 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by KALA BIO Inc.

    144 - KALA BIO, Inc. (0001479419) (Subject)

    3/17/26 4:21:36 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Cardio Diagnostics Holdings Inc.

    10-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

    3/13/26 5:18:52 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACRS
    $ADAP
    $AMAM
    $BBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Leibowitz Arthur S bought $13,405 worth of shares (5,000 units at $2.68), increasing direct ownership by 2% to 291,014 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 9:45:54 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Driscoll Michael Joseph bought $26,688 worth of shares (10,000 units at $2.67), increasing direct ownership by 5% to 225,707 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    3/11/26 5:45:41 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nussdorf Glenn H bought $1,096,039 worth of shares (358,495 units at $3.06) and sold $80,803 worth of shares (22,776 units at $3.55) (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    11/3/25 5:25:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $AMAM
    $BBIO
    Financials

    Live finance-specific insights

    View All

    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co

    3/10/26 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue

    CANTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2025. Fourth Quarter 2025 Financial Results Summary: Net product revenue of $225.1 million for the fourth quarter of 2025, an increase of $98.4 million compared to net product revenue of $126.7 million for the fourth quarter of 2024. Net product revenue for the fourth quarter of 2025 consis

    2/26/26 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $AMAM
    $BBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

    - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line results are expected in the fourth quarter of 2026. "The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrou

    3/18/26 6:55:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

    – Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of John Harlow as the Company's Chief Commercial Officer, effective November 17, 2025. Mr. Harlow will join Esperion's Executive Leadership Team and will report directly to Sheldon Koenig, President and CEO of Esperion.    "We are thrilled to welcome John as our Chief Commercial Officer at such a pivotal time in Esperion's growth, as we continue to expand adoption of our products in the U.S. and increase our global footprint," said Koenig. "John's deep domain expertise

    11/4/25 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

    ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KALA BIO and appointed to the Board of Directors. Mr. Bazemore has served as KALA's interim CEO since February 2025 and previously served as KALA's President and Chief Operating Officer (COO). "Throughout his tenure, including as interim CEO and President and COO, Todd's leadership has been instrumental in driving KALA's clinical progress and str

    9/2/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $AMAM
    $BBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/25/24 11:02:19 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/22/24 4:00:23 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/21/24 4:51:50 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care